RICHARD KINGHAM

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Fast-tracking Approval for Innovative Rare disease therapies (FAIR) Act (H.R. 7953); Ensuring Timely Access to Generics Act of 2025 (S. 3014); Stop STALLING Act (S. 1095); Food & Drug Administration Fiscal Year 2027 Legislative Proposals; Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 (H.R. 8646); Medication Affordability and Patent Integrity Act (S. 2658); Biosimilar Red Tape Elimination Act (S. 1954/H.R. 5526); Expedited Access to Biosimilars Act (S. 1414); Clinical trial regulation; Securing Essential Components for U.S. Readiness in Essential Pharmaceuticals (SECURE Rx) Act of 2026 (discussion draft); Securing Innovation and Research from Adversaries (discussion draft); amendments to the National Childhood Vaccine Injury Act of 1986 and the Vaccine Injury Compensation Program; Destruction of Hazardous Imports Act (H.R. 2715); potential amendments to drug country of origin labeling requirements (discussion draft).

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program Proposed Rule, 91 Fed. Reg. 36236; Medication Affordability and Patent Integrity (MAPIA) Act (S. 2658); Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Expedited Access to Biosimilars Act (S. 1414/ H.R.9661); Biosimilar Red Tape Elimination Act (S. 1954/H.R. 5526); Clinical trial regulation; Community Health Center Clinical Trial Grant Program discussion draft; Alex and Jacis Law discussion draft; Untitled discussion draft on clinical trial regulation (no bill number); Untitled discussion draft on generic drugs intended for use with a device (no bill number); Food & Drug Administration Fiscal Year 2027 Legislative Proposals (no bill number); Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act, (S.3788 / H.R.8269); draft legislation relating to potential improvements the National Childhood Vaccine Injury Act and the Vaccine Injury Compensation Program; American Biotechnology Act, Senate Amendment 6334 to S. 4784, National Defense Authorization Act (NDAA) for Fiscal Year 2027; CARES Act (P.L. 116-136) reporting issues.

Biosimilars Access and Affordability Act (S. 5459); Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Eliminating Thickets to Increase Competition (ETHIC) Act (S. 2276/H.R. 3269); Expedited Access to Biosimilars Act (S. 1414); Biosimilar Red Tape Elimination Act (S. 1954/H.R. 5526); CLEAR Act (H.R.7140); Artificial Intelligence-Ready Data Act (S.4098); Preserve Access to Affordable Generics and Biosimilars Act (S. 1096); Drug Competition Enhancement Act (S.1040); America's Living Library Project Bill (S. 4023); Securing Essential Components for U.S. Readiness in Essential Pharmaceuticals (SECURE Rx) Act of 2026 (discussion draft); improvements to the National Childhood Vaccine Injury Act of 1986; Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act (S. 3788).

Biosimilars Access and Affordability Act (S. 5459); Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Eliminating Thickets to Increase Competition (ETHIC) Act (S. 2276/H.R. 3269); Expedited Access to Biosimilars Act (S. 1414); Biosimilar Red Tape Elimination Act (S. 1954/H.R. 5526); CLEAR Act (H.R.7140); Artificial Intelligence-Ready Data Act (S.4098); Preserve Access to Affordable Generics and Biosimilars Act (S. 1096); Drug Competition Enhancement Act (S.1040); America's Living Library Project Bill (S. 4023); Securing Essential Components for U.S. Readiness in Essential Pharmaceuticals (SECURE Rx) Act of 2026 (discussion draft); improvements to the National Childhood Vaccine Injury Act of 1986; Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act (S. 3788).

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Fast-tracking Approval for Innovative Rare disease therapies (FAIR) Act (H.R. 7953); Ensuring Timely Access to Generics Act of 2025 (S. 3014); Stop STALLING Act (S. 1095); Food & Drug Administration Fiscal Year 2027 Legislative Proposals; Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 (H.R. 8646); Medication Affordability and Patent Integrity Act (S. 2658); Biosimilar Red Tape Elimination Act (S. 1954/H.R. 5526); Expedited Access to Biosimilars Act (S. 1414); Clinical trial regulation; Securing Essential Components for U.S. Readiness in Essential Pharmaceuticals (SECURE Rx) Act of 2026 (discussion draft); Securing Innovation and Research from Adversaries (discussion draft); amendments to the National Childhood Vaccine Injury Act of 1986 and the Vaccine Injury Compensation Program; Destruction of Hazardous Imports Act (H.R. 2715); potential amendments to drug country of origin labeling requirements (discussion draft).

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program Proposed Rule, 91 Fed. Reg. 36236; Medication Affordability and Patent Integrity (MAPIA) Act (S. 2658); Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Expedited Access to Biosimilars Act (S. 1414/ H.R.9661); Biosimilar Red Tape Elimination Act (S. 1954/H.R. 5526); Clinical trial regulation; Community Health Center Clinical Trial Grant Program discussion draft; Alex and Jacis Law discussion draft; Untitled discussion draft on clinical trial regulation (no bill number); Untitled discussion draft on generic drugs intended for use with a device (no bill number); Food & Drug Administration Fiscal Year 2027 Legislative Proposals (no bill number); Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act, (S.3788 / H.R.8269); draft legislation relating to potential improvements the National Childhood Vaccine Injury Act and the Vaccine Injury Compensation Program; American Biotechnology Act, Senate Amendment 6334 to S. 4784, National Defense Authorization Act (NDAA) for Fiscal Year 2027; CARES Act (P.L. 116-136) reporting issues.

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Fast-tracking Approval for Innovative Rare disease therapies (FAIR) Act (H.R. 7953); Ensuring Timely Access to Generics Act of 2025 (S. 3014); Stop STALLING Act (S. 1095); Food & Drug Administration Fiscal Year 2027 Legislative Proposals; Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 (H.R. 8646); Medication Affordability and Patent Integrity Act (S. 2658); Biosimilar Red Tape Elimination Act (S. 1954/H.R. 5526); Expedited Access to Biosimilars Act (S. 1414); Clinical trial regulation; Securing Essential Components for U.S. Readiness in Essential Pharmaceuticals (SECURE Rx) Act of 2026 (discussion draft); Securing Innovation and Research from Adversaries (discussion draft); amendments to the National Childhood Vaccine Injury Act of 1986 and the Vaccine Injury Compensation Program; Destruction of Hazardous Imports Act (H.R. 2715); potential amendments to drug country of origin labeling requirements (discussion draft).

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program Proposed Rule, 91 Fed. Reg. 36236; Medication Affordability and Patent Integrity (MAPIA) Act (S. 2658); Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Expedited Access to Biosimilars Act (S. 1414/ H.R.9661); Biosimilar Red Tape Elimination Act (S. 1954/H.R. 5526); Clinical trial regulation; Community Health Center Clinical Trial Grant Program discussion draft; Alex and Jacis Law discussion draft; Untitled discussion draft on clinical trial regulation (no bill number); Untitled discussion draft on generic drugs intended for use with a device (no bill number); Food & Drug Administration Fiscal Year 2027 Legislative Proposals (no bill number); Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act, (S.3788 / H.R.8269); draft legislation relating to potential improvements the National Childhood Vaccine Injury Act and the Vaccine Injury Compensation Program; American Biotechnology Act, Senate Amendment 6334 to S. 4784, National Defense Authorization Act (NDAA) for Fiscal Year 2027; CARES Act (P.L. 116-136) reporting issues.

Biosimilars Access and Affordability Act (S. 5459); Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Eliminating Thickets to Increase Competition (ETHIC) Act (S. 2276/H.R. 3269); Expedited Access to Biosimilars Act (S. 1414); Biosimilar Red Tape Elimination Act (S. 1954/H.R. 5526); CLEAR Act (H.R.7140); Artificial Intelligence-Ready Data Act (S.4098); Preserve Access to Affordable Generics and Biosimilars Act (S. 1096); Drug Competition Enhancement Act (S.1040); America's Living Library Project Bill (S. 4023); Securing Essential Components for U.S. Readiness in Essential Pharmaceuticals (SECURE Rx) Act of 2026 (discussion draft); improvements to the National Childhood Vaccine Injury Act of 1986; Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act (S. 3788).

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Fast-tracking Approval for Innovative Rare disease therapies (FAIR) Act (H.R. 7953); Ensuring Timely Access to Generics Act of 2025 (S. 3014); Stop STALLING Act (S. 1095); Food & Drug Administration Fiscal Year 2027 Legislative Proposals; Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 (H.R. 8646); Medication Affordability and Patent Integrity Act (S. 2658); Biosimilar Red Tape Elimination Act (S. 1954/H.R. 5526); Expedited Access to Biosimilars Act (S. 1414); Clinical trial regulation; Securing Essential Components for U.S. Readiness in Essential Pharmaceuticals (SECURE Rx) Act of 2026 (discussion draft); Securing Innovation and Research from Adversaries (discussion draft); amendments to the National Childhood Vaccine Injury Act of 1986 and the Vaccine Injury Compensation Program; Destruction of Hazardous Imports Act (H.R. 2715); potential amendments to drug country of origin labeling requirements (discussion draft).

Biosimilars Access and Affordability Act (S. 5459); Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Eliminating Thickets to Increase Competition (ETHIC) Act (S. 2276/H.R. 3269); Expedited Access to Biosimilars Act (S. 1414); Biosimilar Red Tape Elimination Act (S. 1954/H.R. 5526); CLEAR Act (H.R.7140); Artificial Intelligence-Ready Data Act (S.4098); Preserve Access to Affordable Generics and Biosimilars Act (S. 1096); Drug Competition Enhancement Act (S.1040); America's Living Library Project Bill (S. 4023); Securing Essential Components for U.S. Readiness in Essential Pharmaceuticals (SECURE Rx) Act of 2026 (discussion draft); improvements to the National Childhood Vaccine Injury Act of 1986; Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act (S. 3788).

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Fast-tracking Approval for Innovative Rare disease therapies (FAIR) Act (H.R. 7953); Ensuring Timely Access to Generics Act of 2025 (S. 3014); Stop STALLING Act (S. 1095); Food & Drug Administration Fiscal Year 2027 Legislative Proposals; Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 (H.R. 8646); Medication Affordability and Patent Integrity Act (S. 2658); Biosimilar Red Tape Elimination Act (S. 1954/H.R. 5526); Expedited Access to Biosimilars Act (S. 1414); Clinical trial regulation; Securing Essential Components for U.S. Readiness in Essential Pharmaceuticals (SECURE Rx) Act of 2026 (discussion draft); Securing Innovation and Research from Adversaries (discussion draft); amendments to the National Childhood Vaccine Injury Act of 1986 and the Vaccine Injury Compensation Program; Destruction of Hazardous Imports Act (H.R. 2715); potential amendments to drug country of origin labeling requirements (discussion draft).

Biosimilars Access and Affordability Act (S. 5459); Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Eliminating Thickets to Increase Competition (ETHIC) Act (S. 2276/H.R. 3269); Expedited Access to Biosimilars Act (S. 1414); Biosimilar Red Tape Elimination Act (S. 1954/H.R. 5526); CLEAR Act (H.R.7140); Artificial Intelligence-Ready Data Act (S.4098); Preserve Access to Affordable Generics and Biosimilars Act (S. 1096); Drug Competition Enhancement Act (S.1040); America's Living Library Project Bill (S. 4023); Securing Essential Components for U.S. Readiness in Essential Pharmaceuticals (SECURE Rx) Act of 2026 (discussion draft); improvements to the National Childhood Vaccine Injury Act of 1986; Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act (S. 3788).

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program Proposed Rule, 91 Fed. Reg. 36236; Medication Affordability and Patent Integrity (MAPIA) Act (S. 2658); Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Expedited Access to Biosimilars Act (S. 1414/ H.R.9661); Biosimilar Red Tape Elimination Act (S. 1954/H.R. 5526); Clinical trial regulation; Community Health Center Clinical Trial Grant Program discussion draft; Alex and Jacis Law discussion draft; Untitled discussion draft on clinical trial regulation (no bill number); Untitled discussion draft on generic drugs intended for use with a device (no bill number); Food & Drug Administration Fiscal Year 2027 Legislative Proposals (no bill number); Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act, (S.3788 / H.R.8269); draft legislation relating to potential improvements the National Childhood Vaccine Injury Act and the Vaccine Injury Compensation Program; American Biotechnology Act, Senate Amendment 6334 to S. 4784, National Defense Authorization Act (NDAA) for Fiscal Year 2027; CARES Act (P.L. 116-136) reporting issues.

Biosimilars Access and Affordability Act (S. 5459); Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Eliminating Thickets to Increase Competition (ETHIC) Act (S. 2276/H.R. 3269); Expedited Access to Biosimilars Act (S. 1414); Biosimilar Red Tape Elimination Act (S. 1954/H.R. 5526); CLEAR Act (H.R.7140); Artificial Intelligence-Ready Data Act (S.4098); Preserve Access to Affordable Generics and Biosimilars Act (S. 1096); Drug Competition Enhancement Act (S.1040); America's Living Library Project Bill (S. 4023); Securing Essential Components for U.S. Readiness in Essential Pharmaceuticals (SECURE Rx) Act of 2026 (discussion draft); improvements to the National Childhood Vaccine Injury Act of 1986; Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act (S. 3788).

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Fast-tracking Approval for Innovative Rare disease therapies (FAIR) Act (H.R. 7953); Ensuring Timely Access to Generics Act of 2025 (S. 3014); Stop STALLING Act (S. 1095); Food & Drug Administration Fiscal Year 2027 Legislative Proposals; Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 (H.R. 8646); Medication Affordability and Patent Integrity Act (S. 2658); Biosimilar Red Tape Elimination Act (S. 1954/H.R. 5526); Expedited Access to Biosimilars Act (S. 1414); Clinical trial regulation; Securing Essential Components for U.S. Readiness in Essential Pharmaceuticals (SECURE Rx) Act of 2026 (discussion draft); Securing Innovation and Research from Adversaries (discussion draft); amendments to the National Childhood Vaccine Injury Act of 1986 and the Vaccine Injury Compensation Program; Destruction of Hazardous Imports Act (H.R. 2715); potential amendments to drug country of origin labeling requirements (discussion draft).

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program Proposed Rule, 91 Fed. Reg. 36236; Medication Affordability and Patent Integrity (MAPIA) Act (S. 2658); Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Expedited Access to Biosimilars Act (S. 1414/ H.R.9661); Biosimilar Red Tape Elimination Act (S. 1954/H.R. 5526); Clinical trial regulation; Community Health Center Clinical Trial Grant Program discussion draft; Alex and Jacis Law discussion draft; Untitled discussion draft on clinical trial regulation (no bill number); Untitled discussion draft on generic drugs intended for use with a device (no bill number); Food & Drug Administration Fiscal Year 2027 Legislative Proposals (no bill number); Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act, (S.3788 / H.R.8269); draft legislation relating to potential improvements the National Childhood Vaccine Injury Act and the Vaccine Injury Compensation Program; American Biotechnology Act, Senate Amendment 6334 to S. 4784, National Defense Authorization Act (NDAA) for Fiscal Year 2027; CARES Act (P.L. 116-136) reporting issues.

Biosimilars Access and Affordability Act (S. 5459); Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Eliminating Thickets to Increase Competition (ETHIC) Act (S. 2276/H.R. 3269); Expedited Access to Biosimilars Act (S. 1414); Biosimilar Red Tape Elimination Act (S. 1954/H.R. 5526); CLEAR Act (H.R.7140); Artificial Intelligence-Ready Data Act (S.4098); Preserve Access to Affordable Generics and Biosimilars Act (S. 1096); Drug Competition Enhancement Act (S.1040); America's Living Library Project Bill (S. 4023); Securing Essential Components for U.S. Readiness in Essential Pharmaceuticals (SECURE Rx) Act of 2026 (discussion draft); improvements to the National Childhood Vaccine Injury Act of 1986; Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act (S. 3788).

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Fast-tracking Approval for Innovative Rare disease therapies (FAIR) Act (H.R. 7953); Ensuring Timely Access to Generics Act of 2025 (S. 3014); Stop STALLING Act (S. 1095); Food & Drug Administration Fiscal Year 2027 Legislative Proposals; Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 (H.R. 8646); Medication Affordability and Patent Integrity Act (S. 2658); Biosimilar Red Tape Elimination Act (S. 1954/H.R. 5526); Expedited Access to Biosimilars Act (S. 1414); Clinical trial regulation; Securing Essential Components for U.S. Readiness in Essential Pharmaceuticals (SECURE Rx) Act of 2026 (discussion draft); Securing Innovation and Research from Adversaries (discussion draft); amendments to the National Childhood Vaccine Injury Act of 1986 and the Vaccine Injury Compensation Program; Destruction of Hazardous Imports Act (H.R. 2715); potential amendments to drug country of origin labeling requirements (discussion draft).

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program Proposed Rule, 91 Fed. Reg. 36236; Medication Affordability and Patent Integrity (MAPIA) Act (S. 2658); Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Expedited Access to Biosimilars Act (S. 1414/ H.R.9661); Biosimilar Red Tape Elimination Act (S. 1954/H.R. 5526); Clinical trial regulation; Community Health Center Clinical Trial Grant Program discussion draft; Alex and Jacis Law discussion draft; Untitled discussion draft on clinical trial regulation (no bill number); Untitled discussion draft on generic drugs intended for use with a device (no bill number); Food & Drug Administration Fiscal Year 2027 Legislative Proposals (no bill number); Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act, (S.3788 / H.R.8269); draft legislation relating to potential improvements the National Childhood Vaccine Injury Act and the Vaccine Injury Compensation Program; American Biotechnology Act, Senate Amendment 6334 to S. 4784, National Defense Authorization Act (NDAA) for Fiscal Year 2027; CARES Act (P.L. 116-136) reporting issues.

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Fast-tracking Approval for Innovative Rare disease therapies (FAIR) Act (H.R. 7953); Ensuring Timely Access to Generics Act of 2025 (S. 3014); Stop STALLING Act (S. 1095); Food & Drug Administration Fiscal Year 2027 Legislative Proposals; Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 (H.R. 8646); Medication Affordability and Patent Integrity Act (S. 2658); Biosimilar Red Tape Elimination Act (S. 1954/H.R. 5526); Expedited Access to Biosimilars Act (S. 1414); Clinical trial regulation; Securing Essential Components for U.S. Readiness in Essential Pharmaceuticals (SECURE Rx) Act of 2026 (discussion draft); Securing Innovation and Research from Adversaries (discussion draft); amendments to the National Childhood Vaccine Injury Act of 1986 and the Vaccine Injury Compensation Program; Destruction of Hazardous Imports Act (H.R. 2715); potential amendments to drug country of origin labeling requirements (discussion draft).

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program Proposed Rule, 91 Fed. Reg. 36236; Medication Affordability and Patent Integrity (MAPIA) Act (S. 2658); Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Expedited Access to Biosimilars Act (S. 1414/ H.R.9661); Biosimilar Red Tape Elimination Act (S. 1954/H.R. 5526); Clinical trial regulation; Community Health Center Clinical Trial Grant Program discussion draft; Alex and Jacis Law discussion draft; Untitled discussion draft on clinical trial regulation (no bill number); Untitled discussion draft on generic drugs intended for use with a device (no bill number); Food & Drug Administration Fiscal Year 2027 Legislative Proposals (no bill number); Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act, (S.3788 / H.R.8269); draft legislation relating to potential improvements the National Childhood Vaccine Injury Act and the Vaccine Injury Compensation Program; American Biotechnology Act, Senate Amendment 6334 to S. 4784, National Defense Authorization Act (NDAA) for Fiscal Year 2027; CARES Act (P.L. 116-136) reporting issues.

Biosimilars Access and Affordability Act (S. 5459); Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Eliminating Thickets to Increase Competition (ETHIC) Act (S. 2276/H.R. 3269); Expedited Access to Biosimilars Act (S. 1414); Biosimilar Red Tape Elimination Act (S. 1954/H.R. 5526); CLEAR Act (H.R.7140); Artificial Intelligence-Ready Data Act (S.4098); Preserve Access to Affordable Generics and Biosimilars Act (S. 1096); Drug Competition Enhancement Act (S.1040); America's Living Library Project Bill (S. 4023); Securing Essential Components for U.S. Readiness in Essential Pharmaceuticals (SECURE Rx) Act of 2026 (discussion draft); improvements to the National Childhood Vaccine Injury Act of 1986; Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act (S. 3788).

Biosimilars Access and Affordability Act (S. 5459); Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Eliminating Thickets to Increase Competition (ETHIC) Act (S. 2276/H.R. 3269); Expedited Access to Biosimilars Act (S. 1414); Biosimilar Red Tape Elimination Act (S. 1954/H.R. 5526); CLEAR Act (H.R.7140); Artificial Intelligence-Ready Data Act (S.4098); Preserve Access to Affordable Generics and Biosimilars Act (S. 1096); Drug Competition Enhancement Act (S.1040); America's Living Library Project Bill (S. 4023); Securing Essential Components for U.S. Readiness in Essential Pharmaceuticals (SECURE Rx) Act of 2026 (discussion draft); improvements to the National Childhood Vaccine Injury Act of 1986; Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act (S. 3788).

Biosimilars Access and Affordability Act (S. 5459); Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Eliminating Thickets to Increase Competition (ETHIC) Act (S. 2276/H.R. 3269); Expedited Access to Biosimilars Act (S. 1414); Biosimilar Red Tape Elimination Act (S. 1954/H.R. 5526); CLEAR Act (H.R.7140); Artificial Intelligence-Ready Data Act (S.4098); Preserve Access to Affordable Generics and Biosimilars Act (S. 1096); Drug Competition Enhancement Act (S.1040); America's Living Library Project Bill (S. 4023); Securing Essential Components for U.S. Readiness in Essential Pharmaceuticals (SECURE Rx) Act of 2026 (discussion draft); improvements to the National Childhood Vaccine Injury Act of 1986; Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act (S. 3788).

Biosimilars Access and Affordability Act (S. 5459); Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Eliminating Thickets to Increase Competition (ETHIC) Act (S. 2276/H.R. 3269); Expedited Access to Biosimilars Act (S. 1414); Biosimilar Red Tape Elimination Act (S. 1954/H.R. 5526); CLEAR Act (H.R.7140); Artificial Intelligence-Ready Data Act (S.4098); Preserve Access to Affordable Generics and Biosimilars Act (S. 1096); Drug Competition Enhancement Act (S.1040); America's Living Library Project Bill (S. 4023); Securing Essential Components for U.S. Readiness in Essential Pharmaceuticals (SECURE Rx) Act of 2026 (discussion draft); improvements to the National Childhood Vaccine Injury Act of 1986; Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act (S. 3788).

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program Proposed Rule, 91 Fed. Reg. 36236; Medication Affordability and Patent Integrity (MAPIA) Act (S. 2658); Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Expedited Access to Biosimilars Act (S. 1414/ H.R.9661); Biosimilar Red Tape Elimination Act (S. 1954/H.R. 5526); Clinical trial regulation; Community Health Center Clinical Trial Grant Program discussion draft; Alex and Jacis Law discussion draft; Untitled discussion draft on clinical trial regulation (no bill number); Untitled discussion draft on generic drugs intended for use with a device (no bill number); Food & Drug Administration Fiscal Year 2027 Legislative Proposals (no bill number); Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act, (S.3788 / H.R.8269); draft legislation relating to potential improvements the National Childhood Vaccine Injury Act and the Vaccine Injury Compensation Program; American Biotechnology Act, Senate Amendment 6334 to S. 4784, National Defense Authorization Act (NDAA) for Fiscal Year 2027; CARES Act (P.L. 116-136) reporting issues.

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program Proposed Rule, 91 Fed. Reg. 36236; Medication Affordability and Patent Integrity (MAPIA) Act (S. 2658); Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Expedited Access to Biosimilars Act (S. 1414/ H.R.9661); Biosimilar Red Tape Elimination Act (S. 1954/H.R. 5526); Clinical trial regulation; Community Health Center Clinical Trial Grant Program discussion draft; Alex and Jacis Law discussion draft; Untitled discussion draft on clinical trial regulation (no bill number); Untitled discussion draft on generic drugs intended for use with a device (no bill number); Food & Drug Administration Fiscal Year 2027 Legislative Proposals (no bill number); Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act, (S.3788 / H.R.8269); draft legislation relating to potential improvements the National Childhood Vaccine Injury Act and the Vaccine Injury Compensation Program; American Biotechnology Act, Senate Amendment 6334 to S. 4784, National Defense Authorization Act (NDAA) for Fiscal Year 2027; CARES Act (P.L. 116-136) reporting issues.

Biosimilars Access and Affordability Act (S. 5459); Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Eliminating Thickets to Increase Competition (ETHIC) Act (S. 2276/H.R. 3269); Expedited Access to Biosimilars Act (S. 1414); Biosimilar Red Tape Elimination Act (S. 1954/H.R. 5526); CLEAR Act (H.R.7140); Artificial Intelligence-Ready Data Act (S.4098); Preserve Access to Affordable Generics and Biosimilars Act (S. 1096); Drug Competition Enhancement Act (S.1040); America's Living Library Project Bill (S. 4023); Securing Essential Components for U.S. Readiness in Essential Pharmaceuticals (SECURE Rx) Act of 2026 (discussion draft); improvements to the National Childhood Vaccine Injury Act of 1986; Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act (S. 3788).

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biosimilars Access and Affordability Act (S. 5459); Preserve Access to Affordable Generics and Biosimilars Act (S. 1096); EPIC Act of 2025 (S. 832); H.R.1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Increasing Transparency in Generic Drug Applications Act (S.1302); Stop STALLING Act (S. 1095); S. 1040, A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes; Interagency Patent Coordination and Improvement Act of 2025 (S. 1097); approval pathways; Expedited Access to Biosimilars Act (S. 1414); Biosimilar Red Tape Elimination Act (S. 1954); USFDA-PTO collaboration; FDA reductions in force and FDA reforms; drug supply chain; right to try; ORPHAN Cures Act (H.R. 946); H.R.1 - One Big Beautiful Bill Act; priority review vouchers; Family Vaccine Protection Act (H.R. 3701).

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biosimilars Access and Affordability Act (S. 5459); Preserve Access to Affordable Generics and Biosimilars Act (S. 1096); EPIC Act of 2025 (S. 832); H.R.1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Increasing Transparency in Generic Drug Applications Act (S.1302); Stop STALLING Act (S. 1095); S. 1040, A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes; Interagency Patent Coordination and Improvement Act of 2025 (S. 1097); approval pathways; Expedited Access to Biosimilars Act (S. 1414); Biosimilar Red Tape Elimination Act (S. 1954); USFDA-PTO collaboration; FDA reductions in force and FDA reforms; drug supply chain; right to try; ORPHAN Cures Act (H.R. 946); H.R.1 - One Big Beautiful Bill Act; priority review vouchers; Family Vaccine Protection Act (H.R. 3701).

FDA Modernization Act 3.0 (S. 355 / H.R. 2821); Expedited Access to Biosimilars Act (S. 1414); Orphan-drug exclusivity; draft Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act (no bill number); Clinical Trials; Reciprocal approvals; Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Increasing Transparency in Generic Drug Applications Act (S. 1302/H.R. 1843); BIOSECURE Act, Sec. 851 of the Fiscal Year (FY) 2026 National Defense Authorization Act (NDAA)(S. 1071/H.R. 3838); Potential legislation relating to the Vaccine Injury Compensation Program and other issues affecting vaccines.

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biosimilars Access and Affordability Act (no bill number); REMEDY Act (S. 2620); FDA Modernization Act 3.0 (S. 355 / H.R. 2821); issues related to reauthorization of the Prescription Drug User Fee Act (no bill); proposed amendment to the National Defense Authorization Act for Fiscal Year 2026 (S.Amdt.3236 to S.2296); issues related to vaccine access (no bill); Interagency Patent Coordination and Improvement Act of 2025 (S. 1097); Medication Affordability and Patent Integrity Act (S. 2658 / no House bill); Expedited Access to Biosimilars Act (S. 1414); Biosimilar Red Tape Elimination Act (S. 1954, HR 5526); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 (S.2256); conditional approval; orphan-drug exclusivity; FDA reform.

FDA Modernization Act 3.0 (S. 355 / H.R. 2821); Expedited Access to Biosimilars Act (S. 1414); Orphan-drug exclusivity; draft Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act (no bill number); Clinical Trials; Reciprocal approvals; Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Increasing Transparency in Generic Drug Applications Act (S. 1302/H.R. 1843); BIOSECURE Act, Sec. 851 of the Fiscal Year (FY) 2026 National Defense Authorization Act (NDAA)(S. 1071/H.R. 3838); Potential legislation relating to the Vaccine Injury Compensation Program and other issues affecting vaccines.

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biosimilars Access and Affordability Act (S. 5459); Preserve Access to Affordable Generics and Biosimilars Act (S. 1096); EPIC Act of 2025 (S. 832); H.R.1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Increasing Transparency in Generic Drug Applications Act (S.1302); Stop STALLING Act (S. 1095); S. 1040, A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes; Interagency Patent Coordination and Improvement Act of 2025 (S. 1097); approval pathways; Expedited Access to Biosimilars Act (S. 1414); Biosimilar Red Tape Elimination Act (S. 1954); USFDA-PTO collaboration; FDA reductions in force and FDA reforms; drug supply chain; right to try; ORPHAN Cures Act (H.R. 946); H.R.1 - One Big Beautiful Bill Act; priority review vouchers; Family Vaccine Protection Act (H.R. 3701).

FDA Modernization Act 3.0 (S. 355 / H.R. 2821); Expedited Access to Biosimilars Act (S. 1414); Orphan-drug exclusivity; draft Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act (no bill number); Clinical Trials; Reciprocal approvals; Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Increasing Transparency in Generic Drug Applications Act (S. 1302/H.R. 1843); BIOSECURE Act, Sec. 851 of the Fiscal Year (FY) 2026 National Defense Authorization Act (NDAA)(S. 1071/H.R. 3838); Potential legislation relating to the Vaccine Injury Compensation Program and other issues affecting vaccines.

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biosimilars Access and Affordability Act (no bill number); REMEDY Act (S. 2620); FDA Modernization Act 3.0 (S. 355 / H.R. 2821); issues related to reauthorization of the Prescription Drug User Fee Act (no bill); proposed amendment to the National Defense Authorization Act for Fiscal Year 2026 (S.Amdt.3236 to S.2296); issues related to vaccine access (no bill); Interagency Patent Coordination and Improvement Act of 2025 (S. 1097); Medication Affordability and Patent Integrity Act (S. 2658 / no House bill); Expedited Access to Biosimilars Act (S. 1414); Biosimilar Red Tape Elimination Act (S. 1954, HR 5526); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 (S.2256); conditional approval; orphan-drug exclusivity; FDA reform.

FDA Modernization Act 3.0 (S. 355 / H.R. 2821); Expedited Access to Biosimilars Act (S. 1414); Orphan-drug exclusivity; draft Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act (no bill number); Clinical Trials; Reciprocal approvals; Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Increasing Transparency in Generic Drug Applications Act (S. 1302/H.R. 1843); BIOSECURE Act, Sec. 851 of the Fiscal Year (FY) 2026 National Defense Authorization Act (NDAA)(S. 1071/H.R. 3838); Potential legislation relating to the Vaccine Injury Compensation Program and other issues affecting vaccines.

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biosimilars Access and Affordability Act (S. 5459); Preserve Access to Affordable Generics and Biosimilars Act (S. 1096); EPIC Act of 2025 (S. 832); H.R.1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Increasing Transparency in Generic Drug Applications Act (S.1302); Stop STALLING Act (S. 1095); S. 1040, A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes; Interagency Patent Coordination and Improvement Act of 2025 (S. 1097); approval pathways; Expedited Access to Biosimilars Act (S. 1414); Biosimilar Red Tape Elimination Act (S. 1954); USFDA-PTO collaboration; FDA reductions in force and FDA reforms; drug supply chain; right to try; ORPHAN Cures Act (H.R. 946); H.R.1 - One Big Beautiful Bill Act; priority review vouchers; Family Vaccine Protection Act (H.R. 3701).

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biosimilars Access and Affordability Act (S. 5459); Preserve Access to Affordable Generics and Biosimilars Act (S. 1096); EPIC Act of 2025 (S. 832); H.R.1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Increasing Transparency in Generic Drug Applications Act (S.1302); Stop STALLING Act (S. 1095); S. 1040, A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes; Interagency Patent Coordination and Improvement Act of 2025 (S. 1097); approval pathways; Expedited Access to Biosimilars Act (S. 1414); Biosimilar Red Tape Elimination Act (S. 1954); USFDA-PTO collaboration; FDA reductions in force and FDA reforms; drug supply chain; right to try; ORPHAN Cures Act (H.R. 946); H.R.1 - One Big Beautiful Bill Act; priority review vouchers; Family Vaccine Protection Act (H.R. 3701).

FDA Modernization Act 3.0 (S. 355 / H.R. 2821); Expedited Access to Biosimilars Act (S. 1414); Orphan-drug exclusivity; draft Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act (no bill number); Clinical Trials; Reciprocal approvals; Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Increasing Transparency in Generic Drug Applications Act (S. 1302/H.R. 1843); BIOSECURE Act, Sec. 851 of the Fiscal Year (FY) 2026 National Defense Authorization Act (NDAA)(S. 1071/H.R. 3838); Potential legislation relating to the Vaccine Injury Compensation Program and other issues affecting vaccines.

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biosimilars Access and Affordability Act (S. 5459); Preserve Access to Affordable Generics and Biosimilars Act (S. 1096); EPIC Act of 2025 (S. 832); H.R.1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Increasing Transparency in Generic Drug Applications Act (S.1302); Stop STALLING Act (S. 1095); S. 1040, A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes; Interagency Patent Coordination and Improvement Act of 2025 (S. 1097); approval pathways; Expedited Access to Biosimilars Act (S. 1414); Biosimilar Red Tape Elimination Act (S. 1954); USFDA-PTO collaboration; FDA reductions in force and FDA reforms; drug supply chain; right to try; ORPHAN Cures Act (H.R. 946); H.R.1 - One Big Beautiful Bill Act; priority review vouchers; Family Vaccine Protection Act (H.R. 3701).

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biosimilars Access and Affordability Act (S. 5459); Preserve Access to Affordable Generics and Biosimilars Act (S. 1096); EPIC Act of 2025 (S. 832); H.R.1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Increasing Transparency in Generic Drug Applications Act (S.1302); Stop STALLING Act (S. 1095); S. 1040, A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes; Interagency Patent Coordination and Improvement Act of 2025 (S. 1097); approval pathways; Expedited Access to Biosimilars Act (S. 1414); Biosimilar Red Tape Elimination Act (S. 1954); USFDA-PTO collaboration; FDA reductions in force and FDA reforms; drug supply chain; right to try; ORPHAN Cures Act (H.R. 946); H.R.1 - One Big Beautiful Bill Act; priority review vouchers; Family Vaccine Protection Act (H.R. 3701).

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biosimilars Access and Affordability Act (S. 5459); Preserve Access to Affordable Generics and Biosimilars Act (S. 1096); EPIC Act of 2025 (S. 832); H.R.1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Increasing Transparency in Generic Drug Applications Act (S.1302); Stop STALLING Act (S. 1095); S. 1040, A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes; Interagency Patent Coordination and Improvement Act of 2025 (S. 1097); approval pathways; Expedited Access to Biosimilars Act (S. 1414); Biosimilar Red Tape Elimination Act (S. 1954); USFDA-PTO collaboration; FDA reductions in force and FDA reforms; drug supply chain; right to try; ORPHAN Cures Act (H.R. 946); H.R.1 - One Big Beautiful Bill Act; priority review vouchers; Family Vaccine Protection Act (H.R. 3701).

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biosimilars Access and Affordability Act (no bill number); REMEDY Act (S. 2620); FDA Modernization Act 3.0 (S. 355 / H.R. 2821); issues related to reauthorization of the Prescription Drug User Fee Act (no bill); proposed amendment to the National Defense Authorization Act for Fiscal Year 2026 (S.Amdt.3236 to S.2296); issues related to vaccine access (no bill); Interagency Patent Coordination and Improvement Act of 2025 (S. 1097); Medication Affordability and Patent Integrity Act (S. 2658 / no House bill); Expedited Access to Biosimilars Act (S. 1414); Biosimilar Red Tape Elimination Act (S. 1954, HR 5526); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 (S.2256); conditional approval; orphan-drug exclusivity; FDA reform.

FDA Modernization Act 3.0 (S. 355 / H.R. 2821); Expedited Access to Biosimilars Act (S. 1414); Orphan-drug exclusivity; draft Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act (no bill number); Clinical Trials; Reciprocal approvals; Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Increasing Transparency in Generic Drug Applications Act (S. 1302/H.R. 1843); BIOSECURE Act, Sec. 851 of the Fiscal Year (FY) 2026 National Defense Authorization Act (NDAA)(S. 1071/H.R. 3838); Potential legislation relating to the Vaccine Injury Compensation Program and other issues affecting vaccines.

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biosimilars Access and Affordability Act (S. 5459); Preserve Access to Affordable Generics and Biosimilars Act (S. 1096); EPIC Act of 2025 (S. 832); H.R.1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Increasing Transparency in Generic Drug Applications Act (S.1302); Stop STALLING Act (S. 1095); S. 1040, A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes; Interagency Patent Coordination and Improvement Act of 2025 (S. 1097); approval pathways; Expedited Access to Biosimilars Act (S. 1414); Biosimilar Red Tape Elimination Act (S. 1954); USFDA-PTO collaboration; FDA reductions in force and FDA reforms; drug supply chain; right to try; ORPHAN Cures Act (H.R. 946); H.R.1 - One Big Beautiful Bill Act; priority review vouchers; Family Vaccine Protection Act (H.R. 3701).

FDA Modernization Act 3.0 (S. 355 / H.R. 2821); Expedited Access to Biosimilars Act (S. 1414); Orphan-drug exclusivity; draft Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act (no bill number); Clinical Trials; Reciprocal approvals; Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Increasing Transparency in Generic Drug Applications Act (S. 1302/H.R. 1843); BIOSECURE Act, Sec. 851 of the Fiscal Year (FY) 2026 National Defense Authorization Act (NDAA)(S. 1071/H.R. 3838); Potential legislation relating to the Vaccine Injury Compensation Program and other issues affecting vaccines.

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biosimilars Access and Affordability Act (no bill number); REMEDY Act (S. 2620); FDA Modernization Act 3.0 (S. 355 / H.R. 2821); issues related to reauthorization of the Prescription Drug User Fee Act (no bill); proposed amendment to the National Defense Authorization Act for Fiscal Year 2026 (S.Amdt.3236 to S.2296); issues related to vaccine access (no bill); Interagency Patent Coordination and Improvement Act of 2025 (S. 1097); Medication Affordability and Patent Integrity Act (S. 2658 / no House bill); Expedited Access to Biosimilars Act (S. 1414); Biosimilar Red Tape Elimination Act (S. 1954, HR 5526); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 (S.2256); conditional approval; orphan-drug exclusivity; FDA reform.

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biosimilars Access and Affordability Act (S. 5459); Preserve Access to Affordable Generics and Biosimilars Act (S. 1096); EPIC Act of 2025 (S. 832); H.R.1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Increasing Transparency in Generic Drug Applications Act (S.1302); Stop STALLING Act (S. 1095); S. 1040, A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes; Interagency Patent Coordination and Improvement Act of 2025 (S. 1097); approval pathways; Expedited Access to Biosimilars Act (S. 1414); Biosimilar Red Tape Elimination Act (S. 1954); USFDA-PTO collaboration; FDA reductions in force and FDA reforms; drug supply chain; right to try; ORPHAN Cures Act (H.R. 946); H.R.1 - One Big Beautiful Bill Act; priority review vouchers; Family Vaccine Protection Act (H.R. 3701).

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biosimilars Access and Affordability Act (no bill number); REMEDY Act (S. 2620); FDA Modernization Act 3.0 (S. 355 / H.R. 2821); issues related to reauthorization of the Prescription Drug User Fee Act (no bill); proposed amendment to the National Defense Authorization Act for Fiscal Year 2026 (S.Amdt.3236 to S.2296); issues related to vaccine access (no bill); Interagency Patent Coordination and Improvement Act of 2025 (S. 1097); Medication Affordability and Patent Integrity Act (S. 2658 / no House bill); Expedited Access to Biosimilars Act (S. 1414); Biosimilar Red Tape Elimination Act (S. 1954, HR 5526); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 (S.2256); conditional approval; orphan-drug exclusivity; FDA reform.

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biosimilars Access and Affordability Act (S. 5459); Preserve Access to Affordable Generics and Biosimilars Act (S. 1096); EPIC Act of 2025 (S. 832); H.R.1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Increasing Transparency in Generic Drug Applications Act (S.1302); Stop STALLING Act (S. 1095); S. 1040, A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes; Interagency Patent Coordination and Improvement Act of 2025 (S. 1097); approval pathways; Expedited Access to Biosimilars Act (S. 1414); Biosimilar Red Tape Elimination Act (S. 1954); USFDA-PTO collaboration; FDA reductions in force and FDA reforms; drug supply chain; right to try; ORPHAN Cures Act (H.R. 946); H.R.1 - One Big Beautiful Bill Act; priority review vouchers; Family Vaccine Protection Act (H.R. 3701).

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biosimilars Access and Affordability Act (no bill number); REMEDY Act (S. 2620); FDA Modernization Act 3.0 (S. 355 / H.R. 2821); issues related to reauthorization of the Prescription Drug User Fee Act (no bill); proposed amendment to the National Defense Authorization Act for Fiscal Year 2026 (S.Amdt.3236 to S.2296); issues related to vaccine access (no bill); Interagency Patent Coordination and Improvement Act of 2025 (S. 1097); Medication Affordability and Patent Integrity Act (S. 2658 / no House bill); Expedited Access to Biosimilars Act (S. 1414); Biosimilar Red Tape Elimination Act (S. 1954, HR 5526); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 (S.2256); conditional approval; orphan-drug exclusivity; FDA reform.

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biosimilars Access and Affordability Act (no bill number); REMEDY Act (S. 2620); FDA Modernization Act 3.0 (S. 355 / H.R. 2821); issues related to reauthorization of the Prescription Drug User Fee Act (no bill); proposed amendment to the National Defense Authorization Act for Fiscal Year 2026 (S.Amdt.3236 to S.2296); issues related to vaccine access (no bill); Interagency Patent Coordination and Improvement Act of 2025 (S. 1097); Medication Affordability and Patent Integrity Act (S. 2658 / no House bill); Expedited Access to Biosimilars Act (S. 1414); Biosimilar Red Tape Elimination Act (S. 1954, HR 5526); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 (S.2256); conditional approval; orphan-drug exclusivity; FDA reform.

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biosimilars Access and Affordability Act (no bill number); REMEDY Act (S. 2620); FDA Modernization Act 3.0 (S. 355 / H.R. 2821); issues related to reauthorization of the Prescription Drug User Fee Act (no bill); proposed amendment to the National Defense Authorization Act for Fiscal Year 2026 (S.Amdt.3236 to S.2296); issues related to vaccine access (no bill); Interagency Patent Coordination and Improvement Act of 2025 (S. 1097); Medication Affordability and Patent Integrity Act (S. 2658 / no House bill); Expedited Access to Biosimilars Act (S. 1414); Biosimilar Red Tape Elimination Act (S. 1954, HR 5526); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 (S.2256); conditional approval; orphan-drug exclusivity; FDA reform.

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biosimilars Access and Affordability Act (no bill number); REMEDY Act (S. 2620); FDA Modernization Act 3.0 (S. 355 / H.R. 2821); issues related to reauthorization of the Prescription Drug User Fee Act (no bill); proposed amendment to the National Defense Authorization Act for Fiscal Year 2026 (S.Amdt.3236 to S.2296); issues related to vaccine access (no bill); Interagency Patent Coordination and Improvement Act of 2025 (S. 1097); Medication Affordability and Patent Integrity Act (S. 2658 / no House bill); Expedited Access to Biosimilars Act (S. 1414); Biosimilar Red Tape Elimination Act (S. 1954, HR 5526); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 (S.2256); conditional approval; orphan-drug exclusivity; FDA reform.

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biosimilars Access and Affordability Act (no bill number); REMEDY Act (S. 2620); FDA Modernization Act 3.0 (S. 355 / H.R. 2821); issues related to reauthorization of the Prescription Drug User Fee Act (no bill); proposed amendment to the National Defense Authorization Act for Fiscal Year 2026 (S.Amdt.3236 to S.2296); issues related to vaccine access (no bill); Interagency Patent Coordination and Improvement Act of 2025 (S. 1097); Medication Affordability and Patent Integrity Act (S. 2658 / no House bill); Expedited Access to Biosimilars Act (S. 1414); Biosimilar Red Tape Elimination Act (S. 1954, HR 5526); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 (S.2256); conditional approval; orphan-drug exclusivity; FDA reform.

FDA Modernization Act 3.0 (S. 355 / H.R. 2821); Expedited Access to Biosimilars Act (S. 1414); Orphan-drug exclusivity; draft Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act (no bill number); Clinical Trials; Reciprocal approvals; Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Increasing Transparency in Generic Drug Applications Act (S. 1302/H.R. 1843); BIOSECURE Act, Sec. 851 of the Fiscal Year (FY) 2026 National Defense Authorization Act (NDAA)(S. 1071/H.R. 3838); Potential legislation relating to the Vaccine Injury Compensation Program and other issues affecting vaccines.

FDA Modernization Act 3.0 (S. 355 / H.R. 2821); Expedited Access to Biosimilars Act (S. 1414); Orphan-drug exclusivity; draft Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act (no bill number); Clinical Trials; Reciprocal approvals; Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Increasing Transparency in Generic Drug Applications Act (S. 1302/H.R. 1843); BIOSECURE Act, Sec. 851 of the Fiscal Year (FY) 2026 National Defense Authorization Act (NDAA)(S. 1071/H.R. 3838); Potential legislation relating to the Vaccine Injury Compensation Program and other issues affecting vaccines.

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biosimilars Access and Affordability Act (S. 5459); Preserve Access to Affordable Generics and Biosimilars Act (S. 1096); EPIC Act of 2025 (S. 832); H.R.1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Increasing Transparency in Generic Drug Applications Act (S.1302); Stop STALLING Act (S. 1095); S. 1040, A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes; Interagency Patent Coordination and Improvement Act of 2025 (S. 1097); approval pathways; Expedited Access to Biosimilars Act (S. 1414); Biosimilar Red Tape Elimination Act (S. 1954); USFDA-PTO collaboration; FDA reductions in force and FDA reforms; drug supply chain; right to try; ORPHAN Cures Act (H.R. 946); H.R.1 - One Big Beautiful Bill Act; priority review vouchers; Family Vaccine Protection Act (H.R. 3701).

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biosimilars Access and Affordability Act (S. 5459); Preserve Access to Affordable Generics and Biosimilars Act (S. 1096); EPIC Act of 2025 (S. 832); H.R.1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Increasing Transparency in Generic Drug Applications Act (S.1302); Stop STALLING Act (S. 1095); S. 1040, A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes; Interagency Patent Coordination and Improvement Act of 2025 (S. 1097); approval pathways; Expedited Access to Biosimilars Act (S. 1414); Biosimilar Red Tape Elimination Act (S. 1954); USFDA-PTO collaboration; FDA reductions in force and FDA reforms; drug supply chain; right to try; ORPHAN Cures Act (H.R. 946); H.R.1 - One Big Beautiful Bill Act; priority review vouchers; Family Vaccine Protection Act (H.R. 3701).

Implementation and proposed amendments to the Inflation Reduction Act (P.L. 117-169); Innovation in Pediatric Drugs Act of 2023 (H.R. 6664); S.2305 - Biosimilar Red Tape Elimination Act; Promising Pathway Act (S. 1906/H.R.4408); Give Kids a Chance Act of 2023 (H.R. 3433/S.2897); Affordable Prescriptions for Patients Act of 2023 (S. 150); Induced infringement and generic drug labeling; S.3583 - A bill to address patent thickets; REMEDY Act (S. 1209); Biosecure Act (S. 3558); proposed changes to Vaccine Injury Compensation Program.

Implementation and proposed amendments to the Inflation Reduction Act (P.L. 117-169); Innovation in Pediatric Drugs Act of 2023 (H.R. 6664); S.2305 - Biosimilar Red Tape Elimination Act; Promising Pathway Act (S. 1906/H.R.4408); Give Kids a Chance Act of 2023 (H.R. 3433/S.2897); Affordable Prescriptions for Patients Act of 2023 (S. 150); Induced infringement and generic drug labeling; S.3583 - A bill to address patent thickets; REMEDY Act (S. 1209); Biosecure Act (S. 3558); proposed changes to Vaccine Injury Compensation Program.

Implementation and proposed amendments to the Inflation Reduction Act (P.L. 117-169); Innovation in Pediatric Drugs Act of 2023 (H.R. 6664); S.2305 - Biosimilar Red Tape Elimination Act; Promising Pathway Act (S. 1906/H.R.4408); Give Kids a Chance Act of 2023 (H.R. 3433/S.2897); Affordable Prescriptions for Patients Act of 2023 (S. 150); Induced infringement and generic drug labeling; S.3583 - A bill to address patent thickets; REMEDY Act (S. 1209); Biosecure Act (S. 3558); proposed changes to Vaccine Injury Compensation Program.

Implementation and proposed amendments to the Inflation Reduction Act (P.L. 117-169); Innovation in Pediatric Drugs Act of 2023 (H.R. 6664); S.2305 - Biosimilar Red Tape Elimination Act; Promising Pathway Act (S. 1906/H.R.4408); Give Kids a Chance Act of 2023 (H.R. 3433/S.2897); Affordable Prescriptions for Patients Act of 2023 (S. 150); Induced infringement and generic drug labeling; S.3583 - A bill to address patent thickets; REMEDY Act (S. 1209); Biosecure Act (S. 3558); proposed changes to Vaccine Injury Compensation Program.

Implementation and proposed amendments to the Inflation Reduction Act (P.L. 117-169); Innovation in Pediatric Drugs Act of 2023 (H.R. 6664); S.2305 - Biosimilar Red Tape Elimination Act; Promising Pathway Act (S. 1906/H.R.4408); Give Kids a Chance Act of 2023 (H.R. 3433/S.2897); Affordable Prescriptions for Patients Act of 2023 (S. 150); Induced infringement and generic drug labeling; S.3583 - A bill to address patent thickets; REMEDY Act (S. 1209); Biosecure Act (S. 3558); proposed changes to Vaccine Injury Compensation Program.

Implementation and proposed amendments to the Inflation Reduction Act (P.L. 117-169); Innovation in Pediatric Drugs Act of 2023 (H.R. 6664); S.2305 - Biosimilar Red Tape Elimination Act; Promising Pathway Act (S. 1906/H.R.4408); Give Kids a Chance Act of 2023 (H.R. 3433/S.2897); Affordable Prescriptions for Patients Act of 2023 (S. 150); Induced infringement and generic drug labeling; S.3583 - A bill to address patent thickets; REMEDY Act (S. 1209); Biosecure Act (S. 3558); proposed changes to Vaccine Injury Compensation Program.

Implementation and proposed amendments to the Inflation Reduction Act (P.L. 117-169); Innovation in Pediatric Drugs Act of 2023 (H.R. 6664); S.2305 - Biosimilar Red Tape Elimination Act; Promising Pathway Act (S. 1906/H.R.4408); Give Kids a Chance Act of 2023 (H.R. 3433/S.2897); Affordable Prescriptions for Patients Act of 2023 (S. 150); Induced infringement and generic drug labeling; S.3583 - A bill to address patent thickets; REMEDY Act (S. 1209); Biosecure Act (S. 3558); proposed changes to Vaccine Injury Compensation Program.

Implementation and proposed amendments to the Inflation Reduction Act (P.L. 117-169); Innovation in Pediatric Drugs Act of 2023 (H.R. 6664); S.2305 - Biosimilar Red Tape Elimination Act; Promising Pathway Act (S. 1906/H.R.4408); Give Kids a Chance Act of 2023 (H.R. 3433/S.2897); Affordable Prescriptions for Patients Act of 2023 (S. 150); Induced infringement and generic drug labeling; S.3583 - A bill to address patent thickets; REMEDY Act (S. 1209); Biosecure Act (S. 3558); proposed changes to Vaccine Injury Compensation Program.

Implementation and proposed amendments to the Inflation Reduction Act (P.L. 117-169); Innovation in Pediatric Drugs Act of 2023 (H.R. 6664); S.2305 - Biosimilar Red Tape Elimination Act; Promising Pathway Act (S. 1906/H.R.4408); Give Kids a Chance Act of 2023 (H.R. 3433/S.2897); Affordable Prescriptions for Patients Act of 2023 (S. 150); Induced infringement and generic drug labeling; S.3583 - A bill to address patent thickets; REMEDY Act (S. 1209); Biosecure Act (S. 3558); proposed changes to Vaccine Injury Compensation Program.

Implementation and proposed amendments to the Inflation Reduction Act (P.L. 117-169); Innovation in Pediatric Drugs Act of 2023 (H.R. 6664); S.2305 - Biosimilar Red Tape Elimination Act; Promising Pathway Act (S. 1906/H.R.4408); Give Kids a Chance Act of 2023 (H.R. 3433/S.2897); Affordable Prescriptions for Patients Act of 2023 (S. 150); Induced infringement and generic drug labeling; S.3583 - A bill to address patent thickets; REMEDY Act (S. 1209); Biosecure Act (S. 3558); proposed changes to Vaccine Injury Compensation Program.

Maintaining Investments in New Innovation Act (S. 476); Increasing Prescription Drug Competition Act (S. 574); Implementation and proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biologics Competition Act of 2023 (H.R. 1790); Bayh-Dole Act; Affordable Prescriptions for Patients Act of 2023 (S. 150); Stop STALLING Act (S. 148); Increasing Transparency in Generic Drug Applications Act (S. 4338/S. 775); Ensuring Timely Access to Generics Act of 2023 (S. 1067); Taxpayer Research and Contributions Knowledge Act of 2023 (S.315); S.1114 - Expanding Access to Low-Cost Generics Act of 2023; Generic drug labeling and regulation; Method of Use patents and use codes; Potential amendments to S.1339 - Pharmacy Benefit Manager Reform Act; S.6 - Biosimilar Red Tape Elimination Act; H.R.3433 - Give Kids a Chance Act of 2023.

Maintaining Investments in New Innovation Act (S. 476); Increasing Prescription Drug Competition Act (S. 574); Implementation and proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biologics Competition Act of 2023 (H.R. 1790); Bayh-Dole Act; Affordable Prescriptions for Patients Act of 2023 (S. 150); Stop STALLING Act (S. 148); Increasing Transparency in Generic Drug Applications Act (S. 4338/S. 775); Ensuring Timely Access to Generics Act of 2023 (S. 1067); Taxpayer Research and Contributions Knowledge Act of 2023 (S.315); S.1114 - Expanding Access to Low-Cost Generics Act of 2023; Generic drug labeling and regulation; Method of Use patents and use codes; Potential amendments to S.1339 - Pharmacy Benefit Manager Reform Act; S.6 - Biosimilar Red Tape Elimination Act; H.R.3433 - Give Kids a Chance Act of 2023.

Give Kids a Chance Act of 2023 (H.R. 3433); Affordable Prescriptions for Patients Act of 2023 (S. 150); Implementation and proposed amendments to the Inflation Reduction Act (P.L. 117-169); Promising Pathway Act (S. 1906/H.R.4408); Improving Efficiency to Increase Competition Act (H.R. 6684); Use code issues; Opioids regulation; Induced infringement and generic drug labeling; proposed amendments to the National Childhood Vaccine Injury Act and the Public Readiness and Emergency Preparedness (PREP) Act relating to compensation for injuries associated with covered vaccines.

Implementation and proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biosimilar Red Tape Elimination Act (S. 6); Discussion draft of the Primary Care and Health Workforce Act; Biosimilars; Drug compounding; Medication Affordability and Patient Integrity Act (S. 2780/H.R. 5429); Accelerated Approval; Orphan Cures Act (H.R. 5539); Pandemic and All-Hazards Preparedness Act reauthorization bills (S. 2333/H.R. 4220 and 4221).

Give Kids a Chance Act of 2023 (H.R. 3433); Affordable Prescriptions for Patients Act of 2023 (S. 150); Implementation and proposed amendments to the Inflation Reduction Act (P.L. 117-169); Promising Pathway Act (S. 1906/H.R.4408); Improving Efficiency to Increase Competition Act (H.R. 6684); Use code issues; Opioids regulation; Induced infringement and generic drug labeling; proposed amendments to the National Childhood Vaccine Injury Act and the Public Readiness and Emergency Preparedness (PREP) Act relating to compensation for injuries associated with covered vaccines.

Implementation and proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biosimilar Red Tape Elimination Act (S. 6); Discussion draft of the Primary Care and Health Workforce Act; Biosimilars; Drug compounding; Medication Affordability and Patient Integrity Act (S. 2780/H.R. 5429); Accelerated Approval; Orphan Cures Act (H.R. 5539); Pandemic and All-Hazards Preparedness Act reauthorization bills (S. 2333/H.R. 4220 and 4221).

Implementation and proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biosimilar Red Tape Elimination Act (S. 6); Discussion draft of the Primary Care and Health Workforce Act; Biosimilars; Drug compounding; Medication Affordability and Patient Integrity Act (S. 2780/H.R. 5429); Accelerated Approval; Orphan Cures Act (H.R. 5539); Pandemic and All-Hazards Preparedness Act reauthorization bills (S. 2333/H.R. 4220 and 4221).

Give Kids a Chance Act of 2023 (H.R. 3433); Affordable Prescriptions for Patients Act of 2023 (S. 150); Implementation and proposed amendments to the Inflation Reduction Act (P.L. 117-169); Promising Pathway Act (S. 1906/H.R.4408); Improving Efficiency to Increase Competition Act (H.R. 6684); Use code issues; Opioids regulation; Induced infringement and generic drug labeling; proposed amendments to the National Childhood Vaccine Injury Act and the Public Readiness and Emergency Preparedness (PREP) Act relating to compensation for injuries associated with covered vaccines.

Maintaining Investments in New Innovation Act (S. 476); Increasing Prescription Drug Competition Act (S. 574); Implementation and proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biologics Competition Act of 2023 (H.R. 1790); Bayh-Dole Act; Affordable Prescriptions for Patients Act of 2023 (S. 150); Stop STALLING Act (S. 148); Increasing Transparency in Generic Drug Applications Act (S. 4338/S. 775); Ensuring Timely Access to Generics Act of 2023 (S. 1067); Taxpayer Research and Contributions Knowledge Act of 2023 (S.315); S.1114 - Expanding Access to Low-Cost Generics Act of 2023; Generic drug labeling and regulation; Method of Use patents and use codes; Potential amendments to S.1339 - Pharmacy Benefit Manager Reform Act; S.6 - Biosimilar Red Tape Elimination Act; H.R.3433 - Give Kids a Chance Act of 2023.

Maintaining Investments in New Innovation Act (S. 476); Increasing Prescription Drug Competition Act (S. 574); Implementation and proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biologics Competition Act of 2023 (H.R. 1790); Bayh-Dole Act; Affordable Prescriptions for Patients Act of 2023 (S. 150); Stop STALLING Act (S. 148); Increasing Transparency in Generic Drug Applications Act (S. 4338/S. 775); Ensuring Timely Access to Generics Act of 2023 (S. 1067); Taxpayer Research and Contributions Knowledge Act of 2023 (S.315); S.1114 - Expanding Access to Low-Cost Generics Act of 2023; Generic drug labeling and regulation; Method of Use patents and use codes; Potential amendments to S.1339 - Pharmacy Benefit Manager Reform Act; S.6 - Biosimilar Red Tape Elimination Act; H.R.3433 - Give Kids a Chance Act of 2023.

Maintaining Investments in New Innovation Act (S. 476); Increasing Prescription Drug Competition Act (S. 574); Implementation and proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biologics Competition Act of 2023 (H.R. 1790); Bayh-Dole Act; Affordable Prescriptions for Patients Act of 2023 (S. 150); Stop STALLING Act (S. 148); Increasing Transparency in Generic Drug Applications Act (S. 4338/S. 775); Ensuring Timely Access to Generics Act of 2023 (S. 1067); Taxpayer Research and Contributions Knowledge Act of 2023 (S.315); S.1114 - Expanding Access to Low-Cost Generics Act of 2023; Generic drug labeling and regulation; Method of Use patents and use codes; Potential amendments to S.1339 - Pharmacy Benefit Manager Reform Act; S.6 - Biosimilar Red Tape Elimination Act; H.R.3433 - Give Kids a Chance Act of 2023.

Maintaining Investments in New Innovation Act (S. 476); Increasing Prescription Drug Competition Act (S. 574); Implementation and proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biologics Competition Act of 2023 (H.R. 1790); Bayh-Dole Act; Affordable Prescriptions for Patients Act of 2023 (S. 150); Stop STALLING Act (S. 148); Increasing Transparency in Generic Drug Applications Act (S. 4338/S. 775); Ensuring Timely Access to Generics Act of 2023 (S. 1067); Taxpayer Research and Contributions Knowledge Act of 2023 (S.315); S.1114 - Expanding Access to Low-Cost Generics Act of 2023; Generic drug labeling and regulation; Method of Use patents and use codes; Potential amendments to S.1339 - Pharmacy Benefit Manager Reform Act; S.6 - Biosimilar Red Tape Elimination Act; H.R.3433 - Give Kids a Chance Act of 2023.

Maintaining Investments in New Innovation Act (S. 476); Increasing Prescription Drug Competition Act (S. 574); Implementation and proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biologics Competition Act of 2023 (H.R. 1790); Bayh-Dole Act; Affordable Prescriptions for Patients Act of 2023 (S. 150); Stop STALLING Act (S. 148); Increasing Transparency in Generic Drug Applications Act (S. 4338/S. 775); Ensuring Timely Access to Generics Act of 2023 (S. 1067); Taxpayer Research and Contributions Knowledge Act of 2023 (S.315); S.1114 - Expanding Access to Low-Cost Generics Act of 2023; Generic drug labeling and regulation; Method of Use patents and use codes; Potential amendments to S.1339 - Pharmacy Benefit Manager Reform Act; S.6 - Biosimilar Red Tape Elimination Act; H.R.3433 - Give Kids a Chance Act of 2023.

Give Kids a Chance Act of 2023 (H.R. 3433); Affordable Prescriptions for Patients Act of 2023 (S. 150); Implementation and proposed amendments to the Inflation Reduction Act (P.L. 117-169); Promising Pathway Act (S. 1906/H.R.4408); Improving Efficiency to Increase Competition Act (H.R. 6684); Use code issues; Opioids regulation; Induced infringement and generic drug labeling; proposed amendments to the National Childhood Vaccine Injury Act and the Public Readiness and Emergency Preparedness (PREP) Act relating to compensation for injuries associated with covered vaccines.

Give Kids a Chance Act of 2023 (H.R. 3433); Affordable Prescriptions for Patients Act of 2023 (S. 150); Implementation and proposed amendments to the Inflation Reduction Act (P.L. 117-169); Promising Pathway Act (S. 1906/H.R.4408); Improving Efficiency to Increase Competition Act (H.R. 6684); Use code issues; Opioids regulation; Induced infringement and generic drug labeling; proposed amendments to the National Childhood Vaccine Injury Act and the Public Readiness and Emergency Preparedness (PREP) Act relating to compensation for injuries associated with covered vaccines.

Implementation and proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biosimilar Red Tape Elimination Act (S. 6); Discussion draft of the Primary Care and Health Workforce Act; Biosimilars; Drug compounding; Medication Affordability and Patient Integrity Act (S. 2780/H.R. 5429); Accelerated Approval; Orphan Cures Act (H.R. 5539); Pandemic and All-Hazards Preparedness Act reauthorization bills (S. 2333/H.R. 4220 and 4221).

Implementation and proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biosimilar Red Tape Elimination Act (S. 6); Discussion draft of the Primary Care and Health Workforce Act; Biosimilars; Drug compounding; Medication Affordability and Patient Integrity Act (S. 2780/H.R. 5429); Accelerated Approval; Orphan Cures Act (H.R. 5539); Pandemic and All-Hazards Preparedness Act reauthorization bills (S. 2333/H.R. 4220 and 4221).

Maintaining Investments in New Innovation Act (S. 476); Increasing Prescription Drug Competition Act (S. 574); Implementation and proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biologics Competition Act of 2023 (H.R. 1790); Bayh-Dole Act; Affordable Prescriptions for Patients Act of 2023 (S. 150); Stop STALLING Act (S. 148); Increasing Transparency in Generic Drug Applications Act (S. 4338/S. 775); Ensuring Timely Access to Generics Act of 2023 (S. 1067); Taxpayer Research and Contributions Knowledge Act of 2023 (S.315); S.1114 - Expanding Access to Low-Cost Generics Act of 2023; Generic drug labeling and regulation; Method of Use patents and use codes; Potential amendments to S.1339 - Pharmacy Benefit Manager Reform Act; S.6 - Biosimilar Red Tape Elimination Act; H.R.3433 - Give Kids a Chance Act of 2023.

Maintaining Investments in New Innovation Act (S. 476); Increasing Prescription Drug Competition Act (S. 574); Implementation and proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biologics Competition Act of 2023 (H.R. 1790); Bayh-Dole Act; Affordable Prescriptions for Patients Act of 2023 (S. 150); Stop STALLING Act (S. 148); Increasing Transparency in Generic Drug Applications Act (S. 4338/S. 775); Ensuring Timely Access to Generics Act of 2023 (S. 1067); Taxpayer Research and Contributions Knowledge Act of 2023 (S.315); S.1114 - Expanding Access to Low-Cost Generics Act of 2023; Generic drug labeling and regulation; Method of Use patents and use codes; Potential amendments to S.1339 - Pharmacy Benefit Manager Reform Act; S.6 - Biosimilar Red Tape Elimination Act; H.R.3433 - Give Kids a Chance Act of 2023.

Maintaining Investments in New Innovation Act (S. 476); Increasing Prescription Drug Competition Act (S. 574); Implementation and proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biologics Competition Act of 2023 (H.R. 1790); Bayh-Dole Act; Affordable Prescriptions for Patients Act of 2023 (S. 150); Stop STALLING Act (S. 148); Increasing Transparency in Generic Drug Applications Act (S. 4338/S. 775); Ensuring Timely Access to Generics Act of 2023 (S. 1067); Taxpayer Research and Contributions Knowledge Act of 2023 (S.315); S.1114 - Expanding Access to Low-Cost Generics Act of 2023; Generic drug labeling and regulation; Method of Use patents and use codes; Potential amendments to S.1339 - Pharmacy Benefit Manager Reform Act; S.6 - Biosimilar Red Tape Elimination Act; H.R.3433 - Give Kids a Chance Act of 2023.

Maintaining Investments in New Innovation Act (S. 476); Increasing Prescription Drug Competition Act (S. 574); Implementation and proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biologics Competition Act of 2023 (H.R. 1790); Bayh-Dole Act; Affordable Prescriptions for Patients Act of 2023 (S. 150); Stop STALLING Act (S. 148); Increasing Transparency in Generic Drug Applications Act (S. 4338/S. 775); Ensuring Timely Access to Generics Act of 2023 (S. 1067); Taxpayer Research and Contributions Knowledge Act of 2023 (S.315); S.1114 - Expanding Access to Low-Cost Generics Act of 2023; Generic drug labeling and regulation; Method of Use patents and use codes; Potential amendments to S.1339 - Pharmacy Benefit Manager Reform Act; S.6 - Biosimilar Red Tape Elimination Act; H.R.3433 - Give Kids a Chance Act of 2023.

Maintaining Investments in New Innovation Act (S. 476); Increasing Prescription Drug Competition Act (S. 574); Implementation and proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biologics Competition Act of 2023 (H.R. 1790); Bayh-Dole Act; Affordable Prescriptions for Patients Act of 2023 (S. 150); Stop STALLING Act (S. 148); Increasing Transparency in Generic Drug Applications Act (S. 4338/S. 775); Ensuring Timely Access to Generics Act of 2023 (S. 1067); Taxpayer Research and Contributions Knowledge Act of 2023 (S.315); S.1114 - Expanding Access to Low-Cost Generics Act of 2023; Generic drug labeling and regulation; Method of Use patents and use codes; Potential amendments to S.1339 - Pharmacy Benefit Manager Reform Act; S.6 - Biosimilar Red Tape Elimination Act; H.R.3433 - Give Kids a Chance Act of 2023.

Implementation and proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biosimilar Red Tape Elimination Act (S. 6); Discussion draft of the Primary Care and Health Workforce Act; Biosimilars; Drug compounding; Medication Affordability and Patient Integrity Act (S. 2780/H.R. 5429); Accelerated Approval; Orphan Cures Act (H.R. 5539); Pandemic and All-Hazards Preparedness Act reauthorization bills (S. 2333/H.R. 4220 and 4221).

Maintaining Investments in New Innovation Act (S. 476); Increasing Prescription Drug Competition Act (S. 574); Implementation and proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biologics Competition Act of 2023 (H.R. 1790); Bayh-Dole Act; Affordable Prescriptions for Patients Act of 2023 (S. 150); Stop STALLING Act (S. 148); Increasing Transparency in Generic Drug Applications Act (S. 4338/S. 775); Ensuring Timely Access to Generics Act of 2023 (S. 1067); Taxpayer Research and Contributions Knowledge Act of 2023 (S.315); S.1114 - Expanding Access to Low-Cost Generics Act of 2023; Generic drug labeling and regulation; Method of Use patents and use codes; Potential amendments to S.1339 - Pharmacy Benefit Manager Reform Act; S.6 - Biosimilar Red Tape Elimination Act; H.R.3433 - Give Kids a Chance Act of 2023.

Build Back Better Act (H.R. 5376); Increasing Transparency in Generic Drug Applications Act of 2022 (H.R. 7032); Abbreviated approval pathway for biologics; Orphan-drug exclusivity; Cures 2.0 Act (H.R. 6000); Accelerated Approval Integrity Act of 2022 (H.R. 6963); Give Kids a Chance Act (H.R. 6972); Diverse and Equitable Participation in Clinical Trials Act (H.R. 6584); Accelerating Access for Patients Act of 2022 (H.R. 6996); FDA Modernization Act of 2021 (H.R. 2565); PREVENT Pandemics Act (S. 3799) Simplifying the Generic Drug Application Process Act (S. 1462); Prescription Drug User Fee Act Reauthorization; Amendments to the Pediatric Research Equity Act; Right to try; Patent listing issues; Legislation to overrule Genus case; supply chain issues; Advanced Research Project Agency-Health Act (H.R. 5585); America COMPETES Act of 2022 (H.R. 4521)